Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma por Yuncheng Bei (16546095)

Materias:

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma por Yuncheng Bei (16546095)

Materias:

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma por Yuncheng Bei (16546095)

Materias:

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models por Elizabeth R. Tucker (15053624)

Materias:

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models por Elizabeth R. Tucker (15053624)

Materias:

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models por Elizabeth R. Tucker (15053624)

Materias:

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models por Elizabeth R. Tucker (15053624)

Materias:

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models por Elizabeth R. Tucker (15053624)

Materias:

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models por Elizabeth R. Tucker (15053624)

Materias:

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans por Yuanqing Ma (15052437)

Materias:

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans por Yuanqing Ma (15052437)

Materias:

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer por Jonathan Chou (14957015)

Materias:

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans por Yuanqing Ma (15052437)

Materias: